Investor Profile: Calculus Capital — Thesis, Cheque Size & How to Apply

Calculus Capital is a London investment firm founded in 1999 backing entrepreneurial UK companies through tax-efficient venture funds. Led by chief executive and co-founder John Glencross, it has spent over 25 years investing in high-growth smaller companies, and launched the first HMRC-approved Enterprise Investment Scheme fund in 1999. Calculus Capital funding arrives through its funds, and the firm typically backs more developed companies with established products, not very early-stage startups.

Investment thesis

Calculus invests in entrepreneurial businesses with growth potential across the fastest-growing sectors of the UK economy. It builds diversified portfolios of EIS-qualifying companies, targeting £2 tax free for every £1 invested over four to seven years. It seeks strong, adaptable management teams aligned to its growth plans and exit timeframes, and prefers proven business models over raw ideas.

Sectors, stages and fund size

The Calculus EIS Fund invests in technology, healthcare and entertainment companies. The Calculus Knowledge Intensive EIS Fund focuses on healthcare and technology companies doing R&D to create intellectual property, with at least 80 per cent of capital in knowledge-intensive companies. Within technology, Calculus mainly seeks SaaS companies with an established client base; within healthcare, it backs diagnostics, pharmaceutical services and drug discovery firms with large pharma partnerships. It targets full deployment within 12 to 18 months of each close. Total assets under management are not publicly disclosed. Minimum fund investment is £25,000.

Notable portfolio companies

Mo, the employee engagement platform first backed in 2020 alongside Mercia Ventures, was acquired by US giant UKG in 2025, delivering up to 1.8x and £1.53 million in cash for the Calculus VCT. RotaGeek, first invested in during 2020 with a £1.5 million VCT commitment, was sold to Elmo Software in 2025 for just under £2 million. Earlier exits include Synpromics, the Scottish gene-control therapeutics firm acquired by AskBio in 2019, and Horizon Discovery, exited after its AIM listing. Mologic delivered 3.6x on Calculus equity; CloudTrade returned 4x via trade sale.

Partners and team

Calculus is led by chief executive and co-founder John Glencross, who argues the firm's quarter-century in the market keeps it in the flow of exciting opportunities. Co-head of investments Alexander Crawford has publicly praised portfolio teams on exits such as Mo. The firm is authorised and regulated by the Financial Conduct Authority and based at 12 Conduit Street, London.

Programmes, credits and perks

Calculus runs no accelerator and publishes no startup credits bundle. Its offer is structural: investment through EIS and VCT funds, plus a Calculus EIS Reinvestment Fund letting investors recycle exit proceeds into new EIS-qualifying businesses. For founders, the benefit is a patient, tax-efficient investor base and a team experienced in supporting companies to trade sale or flotation within a three to five-year VCT holding window.

How to apply for funding from Calculus Capital

Founders seeking Calculus Capital funding should approach the investment team via calculuscapital.com, with an eye on fit: established products, proven business models and strong teams in technology, healthcare or entertainment. Evidence existing customers or partnerships, a credible four to seven-year growth plan, and a realistic exit route such as trade sale or listing. Because Calculus invests through funds with set close dates, timing matters, so engage early to allow diligence ahead of deployment windows.